NASDAQ$GDRX
GoodRx Holdings Inc. · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
GoodRx's third quarter results exceeded expectations and addressed the grocer issue.
GoodRx's Q3 2022 earnings report revealed a total revenue of $187.3 million, surpassing previous guidance. Despite a net loss of $41.71 million, the company saw double-digit growth in subscription and pharma manufacturer solutions platforms. The company is prioritizing profitability and cash flow.
- Total revenue reached $187.3 million, exceeding prior guidance.
- Net loss amounted to $41.71 million, with a net loss margin of 22.3%.
- Adjusted EBITDA stood at $52.0 million, resulting in an Adjusted EBITDA Margin of 27.8%, also exceeding expectations.
- Net cash provided by operating activities was $33.7 million.
Headline financials
Revenue & EPS history
GoodRx · Revenue · Quarterly
$187M
Revenue by segment
GoodRx · $182M total across 3 segments · Q3 2022
- Prescription Transactions$131M—72.0%
- Subscription$26.5M—14.5%
- Pharma Direct$24.5M—13.4%
Forward guidance
For the fourth quarter, the company anticipates total revenue of approximately $175 million to $180 million and Adjusted EBITDA Margins in the low-to-mid-twenty-percent range.
Tailwinds
- Focus on Adjusted EBITDA growth.
- Focus on margin improvement.
- Focus on cash conversion.
- Actions taken in relation to costs and expenses.
- Reprioritized spending across the business with the objective of greater efficiency.
Headwinds
- Total Revenue ~$175-$180 million
- Year over year change ~(18%) - (16%)
- Includes a combined $45 million to $50 million estimated impact to prescription transactions revenue related to the previously disclosed grocer issue
- Includes continued consumer engagement efforts
- Expect Adjusted EBITDA Margins in the low-to-mid-twenty-percent range.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
-5.3%
Avg return
Earnings day
-8.5%
Avg return
5 days after
-5.0%
Avg return
30 days after
37%
10 / 27 earnings
Positive
+29.1%
Q4 2023
Best reaction
-37.4%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.4% | +10.5% | +3.5% | |
| Q4 2025 | -19.5% | -15.5% | -20.8% | |
| Q3 2025 | +1.8% | -6.1% | -16.9% | |
| Q1 2025 | +11.9% | +13.5% | +7.7% | |
| Q4 2024 | +1.8% | -4.5% | -8.0% | |
| Q3 2024 | -20.0% | -23.1% | -19.6% | |
| Q2 2024 | -16.3% | -20.2% | -10.5% | |
| Q1 2024 | -13.3% | -12.6% | +12.4% | |
| Q4 2023 | +29.1% | +17.6% | +9.7% | |
| Q3 2023 | -12.4% | -8.8% | +9.1% | |
| Q2 2023 | -5.6% | -14.1% | -29.3% | |
| Q1 2023 | +7.0% | +10.9% | +17.5% | |
| Q4 2022 | +5.6% | +13.6% | +14.2% | |
| Q3 2022 | -21.5% | +10.4% | +0.8% | |
| Q2 2022 | +10.5% | +4.1% | -12.6% | |
| Q1 2022 | -37.4% | -30.1% | -43.5% | |
| Q4 2021 | -36.3% | -39.2% | -27.9% | |
| Q3 2021 | -5.7% | -5.1% | -5.4% | |
| Q2 2021 | +20.0% | +13.3% | +37.1% | |
| Q1 2021 | +5.1% | +2.4% | +24.8% | |
| Q4 2018 | -10.5% | -14.2% | -7.9% | |
| Q2 2020 | -3.9% | -7.8% | -1.2% | |
| Q4 2020 | -3.9% | -7.8% | -1.2% | |
| Q1 2020 | -7.3% | -29.1% | -16.5% | |
| Q3 2019 | -7.3% | -29.1% | -16.5% | |
| Q3 2020 | -7.3% | -29.1% | -16.5% | |
| Q4 2019 | -7.3% | -29.1% | -16.5% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro